Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Sumitomo Dainippon Pharma Co. Ltd

Healthcare US DNPUF

9.41USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

10.5010.50
LowHigh

52 Week Range

5.8019.20
LowHigh

Fundamentals

  • Previous Close 9.41
  • Market Cap7101.77M
  • Volume118
  • P/E Ratio6.02
  • Dividend Yield-%
  • EBITDA130002.00M
  • Revenue TTM453394.99M
  • Revenue Per Share TTM1141.22
  • Gross Profit TTM 268585.99M
  • Diluted EPS TTM2.46

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 17611.00M -323114.00000M -47920.00000M 82961.00M 77851.00M
Minority interest -1.00000M -40.00000M 22202.00M 15813.00M 67608.00M
Net income 23634.00M -314969.00000M -74512.00000M 56413.00M 56219.00M
Selling general administrative 135386.00M 429538.00M 373316.00M 249081.00M 190373.00M
Selling and marketing expenses 25000.00M 383621.00M - - -
Gross profit 245395.00M 187981.00M 376625.00M 402908.00M 378179.00M
Reconciled depreciation 25562.00M 37765.00M 41263.00M 38348.00M 22673.00M
Ebit 13023.00M -355136.00000M -44761.00000M 86011.00M 80437.00M
Ebitda 38585.00M -317371.00000M -3498.00000M 124359.00M 103110.00M
Depreciation and amortization 25562.00M 37765.00M 41263.00M 38348.00M 22673.00M
Non operating income net other - - - - -
Operating income 14925.00M -354859.00000M -76979.00000M 60234.00M 71224.00M
Other operating expenses 383907.00M 669417.00M 632523.00M 499801.00M 444728.00M
Interest expense 13500.00M 4277.00M 3159.00M 3050.00M 2586.00M
Tax provision -6024.00000M -8185.00000M 48794.00M 42361.00M 41022.00M
Interest income 2307.00M 36022.00M 32218.00M 25777.00M 9213.00M
Net interest income -11193.00000M 31745.00M 29059.00M 22727.00M 6627.00M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6024.00000M -8185.00000M 48794.00M 42361.00M 41022.00M
Total revenue 398832.00M 314558.00M 555544.00M 560035.00M 515952.00M
Total operating expenses 230470.00M 542840.00M 453604.00M 342674.00M 306955.00M
Cost of revenue 153437.00M 126577.00M 178919.00M 157127.00M 137773.00M
Total other income expense net 2686.00M 31745.00M 29059.00M 22727.00M 6627.00M
Discontinued operations - - - - -
Net income from continuing ops 23635.00M -314929.00000M -96714.00000M 40600.00M 36829.00M
Net income applicable to common shares - - - 56413.00M 56219.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 742604.00M 907506.00M 1134742.00M 1308007.00M 1308127.00M
Intangible assets 172509.00M 195652.00M 329314.00M 398692.00M 383406.00M
Earning assets - - - - -
Other current assets 44150.00M 37064.00M 17675.00M 10420.00M 8342.00M
Total liab 573125.00M 751370.00M 727960.00M 634438.00M 659949.00M
Total stockholder equity 169479.00M 156063.00M 406749.00M 607888.00M 580570.00M
Deferred long term liab - - - - -
Other current liab 154042.00M 155760.00M 229965.00M 207105.00M 203549.00M
Common stock 22400.00M 22400.00M 22400.00M 22400.00M 22400.00M
Capital stock 22400.00M 22400.00M 22400.00M 22400.00M 22400.00M
Retained earnings 46784.00M -22665.00000M 280999.00M 514210.00M 508677.00M
Other liab - - - 102069.00M 106982.00M
Good will 197406.00M 199783.00M 209415.00M 195144.00M 176492.00M
Other assets - - - 22650.00M 20191.00M
Cash 23116.00M 29047.00M 143478.00M 202984.00M 193698.00M
Cash and equivalents - - - - -
Total current liabilities 240603.00M 515474.00M 372694.00M 278373.00M 278147.00M
Current deferred revenue - 1348.00M 151952.00M 140034.00M 147703.00M
Net debt 282306.00M 398817.00M 191238.00M 66064.00M 80121.00M
Short term debt 46440.00M 289298.00M 90588.00M 25085.00M 9960.00M
Short long term debt 46440.00M 285517.00M 90588.00M 25085.00M 9960.00M
Short long term debt total 305422.00M 427864.00M 334716.00M 269048.00M 273819.00M
Other stockholder equity -682.00000M -682.00000M 103350.00M 71278.00M 49493.00M
Property plant equipment - - - 64091.00M 64966.00M
Total current assets 253168.00M 269569.00M 381860.00M 499521.00M 459795.00M
Long term investments - - - - -
Net tangible assets - - - 14052.00M 20672.00M
Short term investments 16840.00M 7085.00M 20174.00M 35596.00M 29480.00M
Net receivables 74840.00M 81023.00M 106128.00M 151500.00M 136060.00M
Long term debt 258982.00M 133367.00M 244128.00M 243963.00M 263859.00M
Inventory 94222.00M 115350.00M 94405.00M 99021.00M 92215.00M
Accounts payable 38544.00M 67720.00M 52141.00M 46183.00M 64638.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 100977.00M 157010.00M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 66751.00M 2239.00M 30566.00M 47661.00M 39722.00M
Deferred long term asset charges - - - - -
Non current assets total 489436.00M 637937.00M 752882.00M 808486.00M 848332.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments 106846.00M 33036.00M 52419.00M -6433.00000M -1225.00000M
Change to liabilities - - - -28669.00000M 50747.00M
Total cashflows from investing activities 99754.00M 33036.00M - -18278.00000M 8875.00M
Net borrowings -112485.00000M 84000.00M - -4931.00000M -24033.00000M
Total cash from financing activities -108836.00000M 77851.00M -146817.00000M -21426.00000M -57215.00000M
Change to operating activities - - - 22803.00M 102102.00M
Net income 23635.00M -314929.00000M -96714.00000M 40600.00M 36829.00M
Change in cash -5931.00000M -114431.00000M -59506.00000M 9286.00M 91990.00M
Begin period cash flow 29047.00M 143478.00M 202984.00M 193698.00M 101708.00M
End period cash flow 23116.00M 29047.00M 143478.00M 202984.00M 193698.00M
Total cash from operating activities 16500.00M -241893.00000M 11937.00M 31239.00M 135601.00M
Issuance of capital stock - - - - -
Depreciation 25562.00M 37765.00M 41263.00M 38348.00M 22673.00M
Other cashflows from investing activities -52.00000M 10000.00M - -797.00000M 225.00M
Dividends paid 3.00M 2792.00M -11125.00000M -11126.00000M -11120.00000M
Change to inventory 18837.00M -11795.00000M 4560.00M 5356.00M -10039.00000M
Change to account receivables -909.00000M 23390.00M - -6097.00000M 185.00M
Sale purchase of stock - - - - -
Other cashflows from financing activities 3652.00M -3357.00000M -115632.00000M -5340.00000M -43135.00000M
Change to netincome - - - -41102.00000M -15829.00000M
Capital expenditures 13030.00M 15730.00M 12742.00M 13494.00M 10806.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -18770.00000M -108115.00000M 34878.00M -33733.00000M 66327.00M
Stock based compensation - - - - -
Other non cash items -13927.00000M 143386.00M 32510.00M -13976.00000M 9772.00M
Free cash flow 3470.00M -257623.00000M -805.00000M 17745.00M 124795.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNPUF
Sumitomo Dainippon Pharma Co. Ltd		 - -% 9.41 6.02 15.22 0.02 3.16 2.28 6.43
ZTS
Zoetis Inc		 -2.135 2.71% 76.58 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.12 0.28% 42.82 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Dainippon Pharma Co. Ltd

6-8, Doshomachi 2-chome, Osaka, Japan, 541-0045

Key Executives

Name Title Year Born
Mr. Hiroshi Nomura CEO, Pres & Representative Director 1957
Hisayoshi Kashima Sr. Director & Corp. Controller NA
Mr. Naoki Noguchi Exec. Officer of Corp. Governance, Corp. Communications & Sr. Director of Corp. Governance NA
Mr. Takuya Taguchi Sr. Exec. Officer & Exe. Director - Sales & Mktg Div. and Deputy Head of Japan Bus. Unit NA
Ms. Atsuko Higuchi Sr.. Exec. Officer of External Affairs, Corp. Secretariat & HR NA
Mr. Yoshiharu Ikeda Ph.D. Sr. Exe. Officer of Cancer, Modality & Drug Research Div., Head of Japan Busi Unit and Director 1958
Mr. Hiroyuki Baba Sr. Exe Off. of Global Data Design, Legal Affairs. IP, IT Mgt, & Frontier Bus. Off. and Director 1959
Mr. Toru Kimura Ph.D. EVP of Global Corp. Strategy, Regenerative & Cellular Medicine Off. and Representative Director 1960
Dr. Shigeyuki Nishinaka Ph.D. Sr. Exe. Officer of Global Bus. Dev. & International Bus. Management and Director 1964
Mr. Hideyuki Harada Sr. Exec. Officer of Tech. Research & Dev. Div., Mfg. Div., Deputy Head of Japan Bus. Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.